Clinical Study Of Feifukang Decoction Combined With Ektorinib In The Treatment Of Advanced Non-small Cell Lung Cancer With Qi And Yin Deficiency And Toxicosis

Objective:Observation the clinical effect of feifukangfang plus Icotinib in treating non-small cell lung cancer in terms of improve life quality,reduce adverse reaction,extent the lifetime and delay the drug resistance.For tumor workers provide effective experience of traditional Chinese medicine prescription.Methods: Select 60 cases into the group to meet the requirements,The treatment group 30 cases(feifukangfang + Icotinib) and control group 30 cases(Icotinib).According to admission order randomly into the treatment group and control group.Control group given Icotinib alone(),125 mg three times a day until disease progression or intolerance to adverse reactions.treatment group given Icotinib plus feifukangfang,Icotinib usage and dosage as well as control group.Feifukangfang water decoction,one does a day,and each 200 ml,three times a day.No longer accept any other anti-tumor treatment during treatment,evaluate the curative effect after 4 weeks of treatment.According to Symptoms integral, KPS to evaluate the results of The quality of life.Based on efficacy evaluation standards of RECIST1.1,Tumor markers to evaluate the results of treatment efficacy.To observe the observed adverse reactions such as rash, diarrhea.According to Routine blood, Liver function,Renal function and ECG to evaluate the results of security.Results:There were all 60 patients that enrolled in this clinical observation with no withdraw during the observation, and the final participants included for medical statistics were 60,that was the treatment group and the control group with 30 patients each one.The results showed Feifukangfang plus Icotinib compared with single Icotinib, in improving the patients' clinical symptoms and improve patients' quality of life, reduce adverse reaction, etc., treatment group was significantly better than the control group,(P<0.05),with the acceptedsecurity. No significant difference were showed between the two groups on the short-term curative effects(P>0.05).Conclusion:Feifukangfang plus Icotinib treating middle-late stage non-small cell lung cancer were superior to single Icotinib on improve patients clinical symptoms and improve patients' quality of life, reduce adverse reaction.